Logos Global Management LP
- SEC CIK
- 0001792126
- Latest filing
- Aug 14, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 53
- +2 vs. Q2 2024
- Portfolio value
- $892.7M
- +$24.8M (+2.9%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| IDYAIDEAYA Biosciences, Inc. | COM | 2,100,000 | $66.5M | 7.5% | +400,000+23.5% | Added | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,250,000 | $54.9M | 6.1% | +150,000+13.6% | Added | History |
| RVMDRevolution Medicines, Inc. | COM | 1,200,000 | $54.4M | 6.1% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 935,000 | $45.9M | 5.1% | +10,000+1.1% | Added | History |
| JANXJanux Therapeutics, Inc. | COM | 1,000,000 | $45.4M | 5.1% | +250,000+33.3% | Added | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 3,208,875 | $38.3M | 4.3% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 300,000 | $34.3M | 3.8% | +300,000 | New | History |
| IMVTImmunovant, Inc. | COM | 1,100,000 | $31.4M | 3.5% | +525,000+91.3% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 900,000 | $30.6M | 3.4% | +900,000 | New | History |
| OCULOcular Therapeutix, Inc | COM | 3,500,000 | $30.4M | 3.4% | −1,650,000−32.0% | Reduced | History |
| IONSIonis Pharmaceuticals Inc | COM | 750,000 | $30.0M | 3.4% | +450,000+150.0% | Added | History |
| ERASErasca, Inc. | COM | 10,900,000 | $29.8M | 3.3% | +5,000,000+84.7% | Added | History |
| MRUSMerus N.V. | COM | 575,000 | $28.7M | 3.2% | −275,000−32.4% | Reduced | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 800,000 | $23.0M | 2.6% | +800,000 | New | History |
| AKROAkero Therapeutics, Inc. | COM | 800,000 | $23.0M | 2.6% | 00.0% | Unchanged | History |
| DSGNDesign Therapeutics, Inc. | COM | 4,217,627 | $22.7M | 2.5% | −814,874−16.2% | Reduced | History |
| VERAVera Therapeutics, Inc. | CL A | 500,000 | $22.1M | 2.5% | −450,000−47.4% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 2,000,000 | $21.6M | 2.4% | +2,000,000 | New | History |
| CYTKCytokinetics Inc | COM NEW | 400,000 | $21.1M | 2.4% | +400,000 | New | History |
| BCAXBicara Therapeutics Inc. | COM | 800,000 | $20.4M | 2.3% | +800,000 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 150,000 | $18.7M | 2.1% | 00.0% | Unchanged | History |
| ANNXAnnexon, Inc. | COM | 2,600,000 | $15.4M | 1.7% | −700,000−21.2% | Reduced | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,100,000 | $15.4M | 1.7% | +1,100,000 | New | History |
| ELVNEnliven Therapeutics, Inc. | COM | 495,000 | $12.6M | 1.4% | −100,000−16.8% | Reduced | History |
| BEAMBeam Therapeutics Inc. | COM | 500,000 | $12.3M | 1.4% | +500,000 | New | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 450,000 | $12.0M | 1.3% | +450,000 | New | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 500,000 | $11.3M | 1.3% | +500,000 | New | History |
| YMABY-mAbs Therapeutics, Inc. | COM | 800,000 | $10.5M | 1.2% | +800,000 | New | History |
| ARVNArvinas, Inc. | COM | 400,000 | $9.85M | 1.1% | +400,000 | New | History |
| TRVITrevi Therapeutics, Inc. | COM | 2,750,000 | $9.19M | 1.0% | −50,000−1.8% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 75,000 | $7.67M | 0.9% | −120,000−61.5% | Reduced | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 1,159,030 | $7.30M | 0.8% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 257,330 | $6.31M | 0.7% | +257,330 | New | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 325,000 | $6.00M | 0.7% | −25,000−7.1% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 200,000 | $5.88M | 0.7% | −375,000−65.2% | Reduced | History |
| DYNDyne Therapeutics, Inc. | COM | 160,000 | $5.75M | 0.6% | −105,000−39.6% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 500,000 | $5.50M | 0.6% | 00.0% | Unchanged | History |
| HELPHelus Pharma Inc. | COM NEW | 600,000 | $5.33M | 0.6% | +600,000 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 800,000 | $5.28M | 0.6% | −400,000−33.3% | Reduced | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 539,079 | $5.12M | 0.6% | 00.0% | Unchanged | History |
| LCTXLineage Cell Therapeutics, Inc. | COM | 5,000,000 | $4.53M | 0.5% | +300,000+6.4% | Added | History |
| RAPPRapport Therapeutics, Inc. | COM | 208,910 | $4.06M | 0.5% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 200,000 | $3.64M | 0.4% | −1,276,061−86.5% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 2,000,000 | $3.52M | 0.4% | −1,000,000−33.3% | Reduced | History |
| NXTCNextCure, Inc. | COM | 2,500,000 | $3.42M | 0.4% | 00.0% | Unchanged | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 416,666 | $2.92M | 0.3% | 00.0% | Unchanged | History |
| ARTVArtiva Biotherapeutics, Inc. | COM | 145,089 | $2.13M | 0.2% | +145,089 | New | History |
| UNCYUnicycive Therapeutics, Inc. | COM | 5,078,927 | $2.07M | 0.2% | +1,609,000+46.4% | Added | History |
| ALLKAllakos Inc. | COM | 2,900,000 | $1.89M | 0.2% | 00.0% | Unchanged | History |
| NMRANeumora Therapeutics, Inc. | COM | 100,000 | $1.32M | 0.1% | −200,000−66.7% | Reduced | History |
| IOBTIO Biotech, Inc. | COM | 493,827 | $518.5K | 0.1% | 00.0% | Unchanged | History |
| SKYESkye Bioscience, Inc. | COM NEW | 100,000 | $391.0K | <0.1% | −1,201,518−92.3% | Reduced | History |
| BOLDBoundless Bio, Inc. | COM | 58,903 | $204.4K | <0.1% | −58,903−50.0% | Reduced | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2024 (13)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| ARGXArgenx SE | SPONSORED ADR | 135,000 | $58.1M | 6.7% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 750,000 | $33.0M | 3.8% | History |
| XNCRXencor Inc | COM | 1,500,000 | $28.4M | 3.3% | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 400,000 | $15.3M | 1.8% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 375,000 | $14.6M | 1.7% | History |
| STOKStoke Therapeutics, Inc. | COM | 1,050,000 | $14.2M | 1.6% | History |
| Cybin Ord23256X100 | COM | 40,000,000 | $10.8M | 1.2% | – |
| ELEVElevation Acquisition Group Inc. | COM | 3,850,000 | $10.4M | 1.2% | History |
| BHVNBiohaven Ltd. | COM | 250,000 | $8.68M | 1.0% | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,300,000 | $8.48M | 1.0% | History |
| APLTApplied Therapeutics, Inc. | COM | 600,000 | $2.66M | 0.3% | History |
| RNACCartesian Therapeutics, Inc. | COM NEW | 90,000 | $2.43M | 0.3% | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 66,666 | $10.7K | <0.1% | – |